查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086947

照護現場分子診斷：市場趨勢、競爭格局與市場預測（2034 年）

Point-of-Care Molecular Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

照護現場分子診斷市場概述

概述：

  • 2025 年照護現場估計為 62 億美元，預計到 2034 年將達到 148 億美元。這一成長是由全球感染疾病負擔加重、向分散式和近患者檢測的轉變以及符合 CLIA 豁免條件的症候群特異性和居家分子檢測的擴展所推動的。
  • 全球照護現場分子診斷市場預計在 2026 年至 2034 年的預測期內將以 10.2% 的複合年成長率成長。
  • 以產品細分市場來看，預計到 2025 年，檢測和耗材細分市場將佔市場佔有率的 58%，從而推動照護現場。
  • 按技術分類，即時PCR技術預計將引領照護現場分子診斷市場，到 2025 年將佔據 45% 的市場佔有率。
  • 按應用領域分類，預計到 2025 年，感染疾病領域將佔市場佔有率的 62%，引領照護現場分子診斷市場。
  • 按最終用戶分類，到 2025 年，醫院和重症監護機構將佔據照護現場地位，市場佔有率為 41%。
  • 預計到 2025 年，北美將以 46% 的銷售額引領全球照護現場分子診斷市場，在全球區域市場佔有率中佔據最高地位。

照護現場分子診斷是指在病患診療場所或其附近，於中心檢查室以外進行的核酸增幅檢查，旨在以檢查室層級的精確度檢測病原體DNA、RNA或遺傳標記。此類別包括小型儀器和分析儀、一次性檢測、試劑盒、試劑和連接軟體，並提供試劑盒式、手持式或無儀器式等多種形式。核心技術包括即時聚合酵素鏈鎖反應(PCR)、恒溫核酸增幅（例如環介導擴增和切口酵素增殖）、基於CRISPR的檢測以及微陣列方法，所有這些技術均旨在滿足REASSURED標準中「快速」、「靈敏」和「特異」的要求，以滿足分散式檢查的需求。主要應用領域包括呼吸道感染疾病、性行為感染感染、院內感染、肝炎、HIV和結核病等傳染病檢查檢測，以及腫瘤和基因檢測。檢測正在醫院、急診室、急診診所、診所、藥房以及越來越多的家庭中得到應用。受 COVID-19 疫情的加速發展，並透過 CLIA 豁免、症候群特異性多重篩檢組合和市售家用檢測套組盒不斷擴展，照護現場分子診斷可提供快速結果，從而實現早期治療，支持合理使用抗生素，並將檢查室品質的檢測帶到患者照護的第一線。

照護現場分子診斷市場的主要市場促進因素

  • 全球感染疾病負擔日益加重，推動了需求成長。世界衛生組織 (WHO) 估計，每年有 3.74 億人感染四種可治療的性行為感染感染，預計到 2023 年將有 1,080 萬人罹患結核病。
  • 對快速、以患者為中心的檢測結果的需求日益成長，導致檢測從集中式檢查室轉移到分散式環境，從而能夠在一次就診中完成診斷和治療。
  • 隨著 CLIA 豁免症候群特異性多參數檢測板（例如 BIOFIRE 的 SPOTFIRE 呼吸道檢測系列）的擴展，檢查室層級的 PCR 檢測正在引入急診室、診所和藥房。
  • 市面上出現了可供購買的家用分子檢測產品，包括 FDA 於 2025 年批准的首個用於性健康的家用 PCR 檢測產品，這正在開闢新的消費管道。
  • 等溫擴增、基於 CRISPR 的檢測以及無需儀器的一次性 PCR 等技術創新正在提高檢測的速度、便攜性和經濟性。
  • 快速分子檢測結果可減少抗生素的不當使​​用，並支持標靶治療，從而優先考慮合理使用抗菌藥物，並推動該技術的普及應用。
  • 感染疾病負擔、醫療保健分散化、監管支援和技術創新等因素的綜合影響預計將推動該市場在 2034 年前實現兩位數成長。

推動照護現場分子診斷市場成長的因素

市場促進因素

全球感染疾病負擔日益加重，抗生素抗藥性問題日益嚴重

照護現場分子診斷市場發展最強勁的動力是持續且日益加重的全球感染疾病負擔。根據世界衛生組織 (WHO) 估計，每年有 3.74 億人感染四種可治療的性行為感染感染，2023 年有 1,080 萬人被診斷出罹患結核病。在美國，疾病管制與預防中心 (CDC) 報告稱，每年新增 160 萬例披衣菌感染病例和超過 70 萬例淋病病例，此外還有流感、呼吸道融合細胞病毒和 COVID-19 等季節性疾病帶來的沉重負擔。抗菌素抗藥性加劇了這個問題，因為無法快速識別病原體導致了經驗性抗生素的使用。即時分子檢測能夠直接、快速地檢測病原體，從而支持更早、更有針對性的治療和感染控制。隨著感染疾病和抗藥性的持續上升，預計到 2034 年，臨床環境和社區對快速分散式分子檢測的需求將會成長。

需要快速獲得患者端檢測結果和分散式醫療保健。

在醫療保健系統中，檢測正從集中式檢查室轉向以病人為中心、分散式的醫療環境。在這些環境中，快速檢測結果可以即時改變臨床決策。床邊分子檢測系統可在15至30分鐘內提供檢查室級的檢測結果，使臨床醫生能夠在一次就診中完成檢測、諮詢和治療，從而改善治療效果並減少後續治療中斷。新冠肺炎疫情凸顯了床邊檢測的價值，急診、急診、診所和藥局對床邊檢測的期望仍然很高。美國疾病管制與預防中心 (CDC) 和美國感染疾病學會 (IDSA) 建議對門診病人進行流感快速分子檢測而非抗原檢測，這支持了分散式分子檢測的臨床有效性。這種即時有效診斷的結構性轉變是推動市場持續成長的動力。

市場限制因素

儘管照護現場分子診斷市場發展勢頭強勁，但仍面臨諸多限制因素。與中心檢查室檢測和快速抗原檢測相比，照護現場分子診斷系統的單次檢測成本仍然較高，而且試劑盒和耗材的持續成本可能會阻礙其在價格敏感型和資源消耗型環境中的普及。不同地區和不同適應症的保險報銷情況不盡相同，分散式和居家分子檢測的保險覆蓋範圍往往落後於臨床應用，從而限制了其普及。監管的複雜性也不容忽視，製造商不僅需要在美國獲得FDA批准和CLIA豁免，還需要遵守更為嚴格的歐洲體外診斷醫療設備法規（IVDR），這導致新檢測方法和平台上市所需時間延長。此外，臨床和分析方面的問題仍然存在，例如某些陰性結果需要中心檢查室確認，以及在非受控環境下檢測性能可能出現差異的風險。消費者自費居家檢測市場缺乏商業性成功案例，例如，儘管獲得了監管部門的批准，家用呼吸道聯合檢測套組卻很快被撤出市場，這凸顯了疫情之外市場需求的不確定性。供應鏈依賴少數供應商提供的設備、試劑盒和供應商，這對供應穩定性和成本帶來了風險。分散地點的人員培訓、網路連接的整合以及品管都增加了營運負擔。儘管感染疾病負擔和分散化趨勢的影響持續存在，但成本、報銷、監管、臨床和營運等方面的障礙正在減緩市場成長速度。

競爭格局

  • 市場集中度：市場高度集中，五家主要公司佔據了大部分銷售額。此外，專有的化學製程和封閉式墨盒系統也構成了很高的進入障礙。
  • 主要公司包括 Danaher (Cepheid)、bioMerieux、F. Hoffmann-La Roche、Abbott 和 QIAGEN，這些公司構成了頂級公司。
  • 地理擴張：領先企業經營全球銷售和支援網路，並正在推行以亞太地區、中東和非洲以及拉丁美洲為目標的業務擴張計劃。
  • 產品系列優勢：領先企業提供涵蓋設備、一次性試劑盒、症候群診斷板和連接軟體的整合產品組合。
  • 產品線優勢：我們擁有活躍的產品線，包括 CLIA 豁免症候群診斷試劑盒、家用和商用檢測套組，以及涵蓋呼吸系統、性健康和其他適應症的擴展測試範圍。
  • 策略合作：我們正透過與遠端醫療、雲端運算和公共衛生領域的合作夥伴開展合作，拓展業務範圍。一個典型的例子是，我們已將居家檢測平台與領先的雲端服務供應商整合。
  • 併購活動：產業重組仍在繼續，例如 BioMérieux 收購 SpinChip Diagnostics 以及 Roche 收購 Lumira DX 的即時檢測技術。
  • 生產能力：大規模生產試劑盒和試劑的能力是重要的競爭優勢，也是供應鏈需要考慮的因素。
  • 創新重點：無需儀器的單次使用 PCR、等溫擴增、基於 CRISPR 的檢測、多項目症候群檢測板和人工智慧驅動的連接。

照護現場分子診斷市場報告的主要結論

  • 對照護現場診斷市場目前市場規模（2025 年）進行分析，並進行 9 年市場預測（2026 年至 2034 年）。
  • 過去三年發生的重大產品和技術開發、合併、收購、合作和合資企業。
  • 引領全球照護現場分子診斷市場的領導公司。
  • 照護現場分子診斷市場為競爭者提供了各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年的表現又會如何？
  • 目前哪些地區、國家在照護現場分子診斷市場表現最佳？
  • 企業應將精力集中在哪些地區或國家，才能掌握照護現場分子診斷市場未來的成長機會？

本「照護現場分子診斷市場」報告的主要讀者。

  • 提供照護現場分子診斷產品的公司。
  • 研究機構和顧問公司
  • 與照護現場分子診斷相關的組織、協會、論壇和其他相關團體。
  • 政府機構和公司
  • 新創公司、創業投資、私募股權公司
  • 銷售代理商和公司負責照護現場分子診斷
  • 這個市場面向各種終端用戶，他們希望了解更多關於照護現場分子診斷市場及其最新技術趨勢的資訊。

常問問題：

問題1：照護現場分子診斷市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，照護現場分子診斷市場將以 10.2% 的複合年成長率成長。

Q2.照護現場分子診斷市場的市場規模有多大？

據估計，2025 年照護現場分子診斷市值為 62 億美元，預計到 2034 年將達到 148 億美元。

Q3. 哪些地區在照護現場分子診斷市場中處於主導？

北美地區擁有密集的製造業基地、先進的分散式檢查基礎設施、完善的FDA核准和CLIA豁免流程、慷慨的保險報銷機制以及較高的呼吸道和性行為感染感染疾病，預計將主導照護現場分子診斷市場，到2025年將佔全球銷售額的46%。亞太地區預計將成為預測期內成長最快的地區。

第四季：照護現場分子診斷市場的主要促進因素是什麼？

主要的驅動力是全球感染疾病負擔日益加重。根據世界衛生組織（世衛組織）估計，2023年將新增3.74億例可治癒的性行為感染和1,080萬例結核病病例。這主要得益於快速、現場、分散式檢查的普及，CLIA豁免的症候群特異性多重檢測試劑盒和市售家用分子檢測的推廣，以及等溫擴增、基於CRISPR的檢測和無儀器PCR等技術的創新。此外，合理使用抗生素也進一步推動了這些趨勢。

Q5.照護現場分子診斷市場的主要參與者有哪些？

領先的公司包括 Danaher Corporation、F. Hoffmann-La Roche Ltd、Abbott Laboratories、bioMerieux SA、QIAGEN NV、Becton, Dickinson and Company、Hologic, Inc.、QuidelOrtho Corporation、Thermo Fisher Scientific Inc. 和 SD Biosensor, Inc.，它們在分佈式盒式檢測領域中佔據主導照護現場環境中的症候群特異性檢測組領域佔據主導地位。

目錄

第1章：照護現場分子診斷市場報告簡介

  • 調查範圍
  • 市場區隔
  • 市場假設

第2章：照護現場分子診斷市場執行摘要

  • 市場概覽

第3章：照護現場分子診斷市場關鍵因素分析

  • 照護現場分子診斷市場：市場促進因素
    • 感染疾病負擔日益加重和抗生素抗藥性問題日益突出
    • 需要能夠快速在患者附近進行的分散式檢查。
    • CLIA豁免和症候群的擴大多重檢測
    • 家用和市售分子檢測的興起
  • 照護現場分子診斷市場的市場限制與挑戰。
    • 每次檢測費用高昂，且報銷金額波動較大。
    • 監管複雜性及向體外診斷醫療器材法規 (IVDR) 的過渡
    • 自籌資金和營運障礙
  • 照護現場分子診斷市場：市場機遇
    • 基於 CRISPR 且無需設備的平台
    • 新興市場和家庭檢測的擴張

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：照護現場分子診斷市場的波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：照護現場分子診斷市場評估

  • 依產品
    • 檢測和耗材
    • 儀器和分析設備
    • 軟體和服務
  • 透過技術
    • 即時PCR
    • 恒溫核酸增幅
    • 利用 CRISPR 進行檢測
    • 微陣列
    • 定序鹼基
    • 其他
  • 透過使用
    • 感染疾病
    • 腫瘤學
    • 基因檢測
  • 最終用戶
    • 醫院及重症監護設施
    • 診所和醫療辦公室
    • 急診及門診護理中心
    • 居家照護和自我檢查
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：照護現場分子診斷市場的競爭格局

  • 市場集中度與結構

第9章：照護現場分子診斷市場新創企業資金籌措與投資趨勢

第10章：照護現場分子診斷市場：公司概況與產品概況

  • Danaher Corporation
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品系列
    • 策略舉措/熵
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • bioMerieux SA
  • QIAGEN NV
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific Inc.
  • SD Biosensor, Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0934

Point-of-Care Molecular Diagnostics Market Summary

Overview:

  • The Point-of-Care Molecular Diagnostics market is estimated at USD 6.20 billion in 2025 and is projected to reach USD 14.80 billion by 2034. Growth is anchored in the rising global burden of infectious disease, the shift toward decentralized and near-patient testing, and the expansion of CLIA-waived syndromic and home molecular tests.
  • The global Point-of-Care Molecular Diagnostics market is growing at a CAGR of 10.2% during the forecast period from 2026 to 2034.
  • By product, the assays and consumables segment dominated the Point-of-Care Molecular Diagnostics market with a 58% share in 2025.
  • By technology, the real-time PCR segment dominated the Point-of-Care Molecular Diagnostics market with a 45% share in 2025.
  • By application, the infectious diseases segment dominated the Point-of-Care Molecular Diagnostics market with a 62% share in 2025.
  • By end user, the hospitals and critical care settings segment dominated the Point-of-Care Molecular Diagnostics market with a 41% share in 2025.
  • North America dominated the global Point-of-Care Molecular Diagnostics market revenue with a 46% share in 2025, representing the highest regional market share globally.

Point-of-care molecular diagnostics refers to nucleic acid amplification testing performed at or near the site of patient care, outside centralized laboratories, to detect the DNA or RNA of pathogens or genetic markers with laboratory-grade accuracy. The category combines compact instruments and analyzers, single-use assays, cartridges, and reagents, and connectivity software, delivered through cartridge-based, handheld, or instrument-free formats. Core technologies include real-time polymerase chain reaction, isothermal nucleic acid amplification such as loop-mediated and nicking-enzyme amplification, CRISPR-based detection, and microarray methods, designed to meet the rapid, sensitive, and specific REASSURED criteria for decentralized testing. Major applications span infectious diseases, including respiratory, sexually transmitted, hospital-acquired, hepatitis, HIV, and tuberculosis testing, as well as oncology and genetic testing. Tests are deployed across hospitals and emergency departments, urgent care, physician offices, pharmacies, and increasingly the home. Accelerated by the COVID-19 pandemic and now expanding through CLIA-waiver, syndromic multiplex panels, and over-the-counter home tests, point-of-care molecular diagnostics deliver rapid results that enable earlier treatment, support antimicrobial stewardship, and bring laboratory-quality testing to the frontline of patient care.

Point-of-Care Molecular Diagnostics Market Key Growth Drivers

  • The rising global burden of infectious disease is expanding demand, with the World Health Organization estimating 374 million new infections each year from four curable sexually transmitted infections and 10.8 million people falling ill with tuberculosis in 2023.
  • Growing demand for rapid, near-patient results is shifting testing from centralized laboratories to decentralized settings, enabling diagnosis and treatment within a single visit.
  • The expansion of CLIA-waived syndromic multiplex panels, such as the BIOFIRE SPOTFIRE respiratory range, is bringing laboratory-grade PCR into urgent care, physician offices, and pharmacies.
  • The emergence of over-the-counter home molecular testing, including the first FDA-authorized at-home PCR test for sexual health in 2025, is opening new consumer channels.
  • Technological innovation in isothermal amplification, CRISPR-based detection, and instrument-free single-use PCR is improving speed, portability, and affordability.
  • Antimicrobial stewardship priorities are driving adoption, as rapid molecular results reduce inappropriate antibiotic use and support targeted therapy.
  • The convergence of infectious disease burden, decentralization, regulatory support, and technological innovation is expected to sustain double-digit growth in the market through 2034.

Key Companies in Point-of-Care Molecular Diagnostics Market

The competitive landscape is led by the following active manufacturers and developers:

  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • bioMerieux SA
  • QIAGEN N.V.
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific Inc.
  • SD Biosensor, Inc.

Factors Contributing to the Growth of the Point-of-Care Molecular Diagnostics Market

Market Drivers

Rising Global Burden of Infectious Disease and Antimicrobial Resistance

The most powerful driver of the Point-of-Care Molecular Diagnostics market is the persistent and rising global burden of infectious disease. The World Health Organization estimates that 374 million new infections occur each year from four curable sexually transmitted infections, and that 10.8 million people fell ill with tuberculosis in 2023. In the United States, the Centers for Disease Control and Prevention reports 1.6 million new chlamydia cases and over 700,000 gonorrhea cases annually, alongside a large seasonal burden of influenza, respiratory syncytial virus, and COVID-19. Antimicrobial resistance compounds the challenge, as the inability to identify pathogens rapidly drives empirical antibiotic use. Point-of-care molecular tests detect pathogens directly and quickly, enabling earlier, targeted treatment and supporting infection control. As infectious disease incidence and resistance continue to rise, demand for rapid decentralized molecular testing expands across clinical and community settings through 2034.

Demand for Rapid, Near-Patient Results and Decentralized Care

Healthcare systems are shifting testing away from centralized laboratories toward near-patient and decentralized settings, where rapid results change clinical decisions in real time. Point-of-care molecular systems deliver laboratory-grade results in 15 to 30 minutes, allowing clinicians to test, counsel, and treat within a single visit, which improves outcomes and reduces loss to follow-up. The COVID-19 pandemic demonstrated the value of testing at the patient bedside, and that expectation has persisted across emergency departments, urgent care, physician offices, and pharmacies. The Centers for Disease Control and Prevention and the Infectious Diseases Society of America recommend rapid molecular assays over antigen tests for influenza in outpatients, reinforcing the clinical case for decentralized molecular testing. This structural shift toward immediate, actionable diagnosis is a sustained driver of market growth.

Market Restraints

Despite strong momentum, the Point-of-Care Molecular Diagnostics market faces material constraints. The cost per test for molecular point-of-care systems remains higher than for central-laboratory testing and rapid antigen alternatives, with cartridge and consumable expenditure adding recurring cost that can limit adoption in price-sensitive and lower-resource settings. Reimbursement is uneven across geographies and indications, and coverage for decentralized and home molecular testing often lags clinical availability, constraining utilization. Regulatory complexity is significant, as manufacturers must navigate FDA clearance and CLIA-waiver pathways in the United States and the more demanding European In Vitro Diagnostic Regulation, lengthening time to market for new assays and platforms. Clinical and analytical concerns persist, including the need to confirm certain negative results in centralized laboratories and the risk of variable performance outside controlled settings. The consumer-pay home market remains commercially unproven, illustrated by the withdrawal of an early at-home combination respiratory test despite regulatory success, underscoring uncertain demand outside pandemic conditions. Supply chains are exposed through reliance on a concentrated set of instrument, cartridge, and reagent suppliers, creating availability and cost risk. Workforce training, connectivity integration, and quality oversight across distributed sites add operational burden. Together, these cost, reimbursement, regulatory, clinical, and operational barriers temper the pace of growth, even as the underlying drivers of infectious disease burden and decentralization remain firmly intact.

Point-of-Care Molecular Diagnostics Market Segment Analysis

The Point-of-Care Molecular Diagnostics Market by Product (Assays and Consumables, Instruments and Analyzers, Software and Services), Technology (Real-Time PCR, Isothermal Nucleic Acid Amplification, CRISPR-Based Detection, Microarray, Sequencing-Based, Others), Application (Infectious Diseases, Oncology, Genetic Testing, Others), End User (Hospitals and Critical Care Settings, Physician Offices and Clinics, Urgent Care and Ambulatory Centers, Home Care and Self-Testing, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Assays and Consumables. The assays and consumables category is expected to dominate the market.

Dominant: Assays and Consumables ~ 58%

The assays and consumables segment accounted for 58% of the Point-of-Care Molecular Diagnostics market in 2025. Assays and consumables are the leading product segment because point-of-care molecular testing operates on a razor-and-blade model in which single-use cartridges, reagents, and test kits are consumed on every run, producing recurring revenue that scales directly with testing volume. As decentralized testing expands across respiratory, sexual health, and other indications, consumable demand deepens with each new installed instrument. Manufacturers reinforce this dynamic by pairing proprietary platforms with closed-system cartridges, locking testing sites into ongoing purchases, as seen with Cepheid GeneXpert cartridges and BIOFIRE SPOTFIRE panels. A steady cadence of new assay launches, including CLIA-waived syndromic respiratory and sore-throat panels and the first over-the-counter PCR sexual health test, continuously expands the consumable menu. The combination of recurring economics, growing test volumes, and menu expansion secures the segment's leadership across the forecast period, while the instruments and analyzers tier underpins the installed base and the software and services tier captures connectivity, data, and support revenue.

By Technology

Dominant Subsegment: Real-Time PCR. The real-time PCR category is expected to dominate the market.

Dominant: Real-Time PCR ~ 45%

The real-time PCR segment accounted for 45% of the Point-of-Care Molecular Diagnostics market in 2025. Real-time polymerase chain reaction is the most widely deployed point-of-care molecular technology, valued as the diagnostic gold standard for its high sensitivity, specificity, and broad validated assay menu. Its dominance is reinforced by large installed bases of cartridge-based PCR platforms such as Cepheid GeneXpert, Roche cobas liat, and bioMerieux BIOFIRE SPOTFIRE, and by professional guidelines that recommend nucleic acid amplification testing over rapid antigen tests for conditions such as influenza. Continued innovation sustains the segment, including instrument-free single-use PCR devices that deliver laboratory-grade results in the palm of the hand and multiplex panels that detect many pathogens simultaneously. Adjacent technologies are advancing rapidly: isothermal nucleic acid amplification enables low-power, instrument-light testing, and CRISPR-based detection is expected to be among the fastest-growing approaches. While these alternatives expand the technology landscape and grow quickly from smaller bases, real-time PCR retains leadership through its accuracy, versatility, and entrenched clinical validation across the forecast period.

By End User

Dominant Subsegment: Hospitals and Critical Care Settings. The hospitals and critical care settings category is expected to dominate the market.

Dominant: Hospitals and Critical Care Settings ~ 41%

The hospitals and critical care settings segment accounted for 41% of the Point-of-Care Molecular Diagnostics market in 2025. Hospitals and critical care settings are the largest end user because emergency departments, intensive care units, and hospital-based near-patient testing sites combine high testing volumes with the greatest clinical urgency. Rapid molecular results in these settings guide isolation, admission, and treatment decisions for respiratory, bloodstream, and hospital-acquired infections, where delays carry serious consequences. Hospitals have the infrastructure, accreditation, and throughput to deploy multiple molecular platforms and syndromic panels, and they anchor the installed base for cartridge-based systems. The clinical case is reinforced by antimicrobial stewardship programs that depend on rapid pathogen identification. At the same time, the expansion of CLIA-waived testing is driving rapid growth in physician offices, urgent care and ambulatory centers, and the emerging home-care and self-testing channel, as molecular testing moves closer to the patient. While these decentralized settings are the fastest-expanding cohort, hospitals and critical care settings retain leadership in 2025 on the strength of volume, acuity, and infrastructure.

Point-of-Care Molecular Diagnostics Market Region Analysis

Dominant Region: North America

North America accounted for 46% of the global Point-of-Care Molecular Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the concentration of leading molecular diagnostics manufacturers, an advanced healthcare infrastructure, and the most active decentralized testing environment, particularly in the United States. Market-size influence is amplified by high per-capita testing volumes, strong reimbursement for molecular diagnostics, and rapid uptake of CLIA-waived syndromic panels in urgent care, physician offices, and pharmacies. The regulatory environment is supportive, with established FDA clearance and CLIA-waiver pathways and a series of landmark authorizations, including the first over-the-counter PCR sexual health test in 2025 and CLIA-waived BIOFIRE SPOTFIRE respiratory panels in 2024. Disease burden is substantial, with the Centers for Disease Control and Prevention reporting 1.6 million new chlamydia cases and over 700,000 gonorrhea cases annually alongside heavy seasonal respiratory demand. A deep manufacturer base and strong private and public investment anchor the region's continued leadership.

Dominant: North America ~ 46% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Point-of-Care Molecular Diagnostics market. The region's elevated CAGR is driven by a large population, a high burden of infectious disease including tuberculosis and respiratory and sexually transmitted infections, and expanding access to decentralized testing across China, India, Japan, South Korea, and Australia. Rising healthcare investment, government infectious-disease surveillance programs, and the growth of affordable domestic platforms such as chip-based real-time micro-PCR systems are broadening access in both urban and remote settings. Manufacturing expansion and local innovation are lowering costs and accelerating adoption, while increasing awareness, urbanization, and insurance coverage support demand. The combination of high disease burden, decentralization, and cost-effective regional platforms positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 46% of the global Point-of-Care Molecular Diagnostics market revenue in 2025. The United States dominates on the strength of its manufacturer base, decentralized testing infrastructure, CLIA-waiver and FDA pathways, and strong reimbursement, while Canada contributes through public-health testing programs and expanding near-patient diagnostics in primary and remote care.

Europe

Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong public health systems, antimicrobial stewardship initiatives, and rising syndromic testing, while the transition to the European In Vitro Diagnostic Regulation is raising the evidence bar for new point-of-care molecular assays and shaping market entry across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large population, a high infectious-disease burden, and expanding access to decentralized testing across China, India, Japan, South Korea, and Australia. Affordable domestic platforms, government surveillance programs, and rising healthcare investment are accelerating adoption in both clinical and community settings.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. A high burden of tuberculosis, HIV, and other infectious diseases, combined with limited centralized laboratory capacity, makes rapid decentralized molecular testing especially valuable, and international health programs and donor funding are expanding access to point-of-care platforms across these markets.

Point-of-Care Molecular Diagnostics Market Competitive Landscape

The Point-of-Care Molecular Diagnostics market is classified as Consolidated. A small group of global diagnostics companies controls the majority of platform and consumable revenue, with Danaher leading through its Cepheid GeneXpert systems, followed by bioMerieux in syndromic testing, Roche and Abbott in cartridge-based and rapid molecular platforms, and QIAGEN in portable systems. A broad and active field of specialized challengers, including Visby Medical, Co-Diagnostics, Molbio Diagnostics, and SD Biosensor, competes in instrument-free, home, and emerging-market segments.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Consolidated, with the top five players holding the majority of revenue and high barriers to entry from proprietary chemistry and closed-cartridge ecosystems.
  • Leading players: Danaher (Cepheid), bioMerieux, F. Hoffmann-La Roche, Abbott, and QIAGEN anchor the top tier.
  • Geographic reach: Leaders operate global commercial and support networks, with expansion programs targeting Asia-Pacific, the Middle East, Africa, and Latin America.
  • Product portfolio strength: Top players offer integrated portfolios spanning instruments, single-use cartridges, syndromic panels, and connectivity software.
  • Pipeline strength: Active pipelines in CLIA-waived syndromic panels, home and over-the-counter assays, and expanded menus across respiratory, sexual health, and other indications.
  • Strategic partnerships: Collaborations with telehealth, cloud, and public-health partners extend reach, exemplified by home testing platforms integrated with major cloud providers.
  • M&A activity: Consolidation continues, including bioMerieux's acquisition of SpinChip Diagnostics and Roche's acquisition of LumiraDx point-of-care technology.
  • Manufacturing capabilities: Scale manufacturing of cartridges and reagents is a key competitive moat and a supply-chain consideration.
  • Innovation focus: Instrument-free single-use PCR, isothermal amplification, CRISPR-based detection, multiplex syndromic panels, and AI-enabled connectivity.

Point-of-Care Molecular Diagnostics Market Recent Developmental Activities

In June 2025, Danaher Corporation (Cepheid), received a Health Canada medical device license for the Xpert HIV-1 Viral Load XC, a next-generation extended-coverage test used to monitor the effectiveness of antiretroviral therapy. Strategic significance: Extends decentralized molecular monitoring into HIV care and strengthens Cepheid's GeneXpert menu for global health programs.

In March 2025, Visby Medical, Inc., received FDA De Novo authorization for the Visby Medical Women's Sexual Health Test, the first over-the-counter PCR diagnostic authorized for home use for any indication, detecting chlamydia, gonorrhea, and trichomoniasis in 30 minutes. Strategic significance: Opens the at-home PCR market and establishes instrument-free molecular testing as a consumer category.

Point-of-Care Molecular Diagnostics Market Segmentation

Point-of-Care Molecular Diagnostics Market by Product

  • Assays and Consumables
  • Instruments and Analyzers
  • Software and Services

Point-of-Care Molecular Diagnostics Market by Technology

  • Real-Time PCR
  • Isothermal Nucleic Acid Amplification
  • CRISPR-Based Detection
  • Microarray
  • Sequencing-Based
  • Others

Point-of-Care Molecular Diagnostics Market by Application

  • Infectious Diseases
  • Respiratory Infections
  • Sexually Transmitted Infections
  • Hospital-Acquired Infections
  • Hepatitis and HIV
  • Tuberculosis
  • Oncology
  • Genetic Testing
  • Others

Point-of-Care Molecular Diagnostics Market by End User

  • Hospitals and Critical Care Settings
  • Physician Offices and Clinics
  • Urgent Care and Ambulatory Centers
  • Home Care and Self-Testing
  • Others

Point-of-Care Molecular Diagnostics Market by Geography

  • North America Point-of-Care Molecular Diagnostics Market
  • United States Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Canada Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Mexico Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Europe Point-of-Care Molecular Diagnostics Market
  • Germany Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • United Kingdom Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • France Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Italy Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Spain Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Rest of Europe Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Asia-Pacific Point-of-Care Molecular Diagnostics Market
  • China Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Japan Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • India Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Australia Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • South Korea Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Point-of-Care Molecular Diagnostics Market
  • Middle East Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • Africa Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
  • South America Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Point-of-Care Molecular Diagnostics Market Report Study

  • Market size analysis for the current Point-of-Care molecular diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global Point-of-Care molecular diagnostics market.
  • Various opportunities available for competitors in the Point-of-Care molecular diagnostics market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Point-of-Care molecular diagnostics market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for Point-of-Care molecular diagnostics market growth in the future?

Target audience who can benefit from this Point-of-Care molecular diagnostics market report study

  • Point-of-Care Molecular Diagnostics product providers
  • Research organizations and consulting companies
  • Point-of-Care Molecular Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Point-of-Care molecular diagnostics
  • Various end-users who want to know more about the Point-of-Care molecular diagnostics market and the latest technological developments in the Point-of-Care molecular diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Point-of-Care Molecular Diagnostics market?

The Point-of-Care Molecular Diagnostics market is projected to expand at a CAGR of 10.2% during the forecast period from 2026-2034.

Q2. What is the market size of the Point-of-Care Molecular Diagnostics market?

The Point-of-Care Molecular Diagnostics market is estimated at USD 6.20 billion in 2025 and is projected to reach USD 14.80 billion by 2034.

Q3. Which region dominates the Point-of-Care Molecular Diagnostics market?

North America dominated the Point-of-Care Molecular Diagnostics market with a 46% share of global revenue in 2025, supported by a dense base of manufacturers, advanced decentralized testing infrastructure, established FDA clearance and CLIA-waiver pathways, strong reimbursement, and a high burden of respiratory and sexually transmitted infections. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Point-of-Care Molecular Diagnostics market?

The principal drivers are the rising global burden of infectious disease, with the World Health Organization estimating 374 million new curable sexually transmitted infections each year and 10.8 million tuberculosis cases in 2023; the shift toward rapid, near-patient, decentralized testing; the expansion of CLIA-waived syndromic multiplex panels and over-the-counter home molecular tests; and technological innovation in isothermal amplification, CRISPR-based detection, and instrument-free PCR, reinforced by antimicrobial stewardship priorities.

Q5. Who are the major players in the Point-of-Care Molecular Diagnostics market?

The major players include Danaher Corporation, F. Hoffmann-La Roche Ltd, Abbott Laboratories, bioMerieux SA, QIAGEN N.V., Becton, Dickinson and Company, Hologic, Inc., QuidelOrtho Corporation, Thermo Fisher Scientific Inc., and SD Biosensor, Inc., among other active manufacturers profiled in the Competitive Landscape section, along with specialized developers such as Visby Medical, Co-Diagnostics, and Molbio Diagnostics. Danaher's Cepheid leads in decentralized cartridge-based testing, while bioMerieux leads in point-of-care syndromic panels.

Table of Contents

1. Point-of-Care Molecular Diagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Point-of-Care Molecular Diagnostics Market Executive Summary

  • 2.1 Market at a Glance

3. Point-of-Care Molecular Diagnostics Market Key Factors Analysis

  • 3.1 Point-of-Care Molecular Diagnostics Market Drivers
    • 3.1.1 Rising Burden of Infectious Disease and Antimicrobial Resistance
    • 3.1.2 Demand for Rapid, Near-Patient, Decentralized Testing
    • 3.1.3 Expansion of CLIA-Waiver and Syndromic Multiplex Testing
    • 3.1.4 Emergence of Home and Over-the-Counter Molecular Testing
  • 3.2 Point-of-Care Molecular Diagnostics Market Restraints and Challenges
    • 3.2.1 High Cost per Test and Reimbursement Variability
    • 3.2.2 Regulatory Complexity and IVDR Transition
    • 3.2.3 Consumer-Pay and Operational Barriers
  • 3.3 Point-of-Care Molecular Diagnostics Market Opportunities
    • 3.3.1 CRISPR-Based and Instrument-Free Platforms
    • 3.3.2 Emerging-Market and Home Testing Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Point-of-Care Molecular Diagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Point-of-Care Molecular Diagnostics Market Assessment

  • 7.1 By Product
    • 7.1.1 Assays and Consumables
    • 7.1.2 Instruments and Analyzers
    • 7.1.3 Software and Services
  • 7.2 By Technology
    • 7.2.1 Real-Time PCR
    • 7.2.2 Isothermal Nucleic Acid Amplification
    • 7.2.3 CRISPR-Based Detection
    • 7.2.4 Microarray
    • 7.2.5 Sequencing-Based
    • 7.2.6 Others
  • 7.3 By Application
    • 7.3.1 Infectious Diseases
      • 7.3.1.1 Respiratory Infections
      • 7.3.1.2 Sexually Transmitted Infections
      • 7.3.1.3 Hospital-Acquired Infections
      • 7.3.1.4 Hepatitis and HIV
      • 7.3.1.5 Tuberculosis
    • 7.3.2 Oncology
    • 7.3.3 Genetic Testing
    • 7.3.4 Others
  • 7.4 By End User
    • 7.4.1 Hospitals and Critical Care Settings
    • 7.4.2 Physician Offices and Clinics
    • 7.4.3 Urgent Care and Ambulatory Centers
    • 7.4.4 Home Care and Self-Testing
    • 7.4.5 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 Germany Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.2.2 United Kingdom Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.2.3 France Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.3.3 India Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
    • 7.5.4 Rest of World
      • 7.5.4.1 Middle East Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Point-of-Care Molecular Diagnostics Market Size in USD million (2023-2034)

8. Point-of-Care Molecular Diagnostics Market Competitive Landscape

  • 8.1 Market Concentration and Structure

9. Point-of-Care Molecular Diagnostics Market Startup Funding and Investment Trends

10. Point-of-Care Molecular Diagnostics Market Company and Product Profiles

  • 10.1 Danaher Corporation
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 F. Hoffmann-La Roche Ltd
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Abbott Laboratories
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 bioMerieux SA
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 QIAGEN N.V.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Hologic, Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 QuidelOrtho Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Thermo Fisher Scientific Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 SD Biosensor, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Point-of-Care Molecular Diagnostics Market in Global (2023-2034)
  • Table 2: Point-of-Care Molecular Diagnostics Market in Global by Product (2023-2034)
  • Table 3: Point-of-Care Molecular Diagnostics Market in Global by Technology (2023-2034)
  • Table 4: Point-of-Care Molecular Diagnostics Market in Global by Application (2023-2034)
  • Table 5: Point-of-Care Molecular Diagnostics Market in Global by End User (2023-2034)
  • Table 6: Point-of-Care Molecular Diagnostics Market in Global by Geography (2023-2034)
  • Table 7: Point-of-Care Molecular Diagnostics Market in North America (2023-2034)
  • Table 8: Point-of-Care Molecular Diagnostics Market in the United States (2023-2034)
  • Table 9: Point-of-Care Molecular Diagnostics Market in Canada (2023-2034)
  • Table 10: Point-of-Care Molecular Diagnostics Market in Mexico (2023-2034)
  • Table 11: Point-of-Care Molecular Diagnostics Market in Europe (2023-2034)
  • Table 12: Point-of-Care Molecular Diagnostics Market in Germany (2023-2034)
  • Table 13: Point-of-Care Molecular Diagnostics Market in United Kingdom (2023-2034)
  • Table 14: Point-of-Care Molecular Diagnostics Market in France (2023-2034)
  • Table 15: Point-of-Care Molecular Diagnostics Market in Italy (2023-2034)
  • Table 16: Point-of-Care Molecular Diagnostics Market in Spain (2023-2034)
  • Table 17: Point-of-Care Molecular Diagnostics Market in the Rest of Europe (2023-2034)
  • Table 18: Point-of-Care Molecular Diagnostics Market in Asia-Pacific (2023-2034)
  • Table 19: Point-of-Care Molecular Diagnostics Market in China (2023-2034)
  • Table 20: Point-of-Care Molecular Diagnostics Market in Japan (2023-2034)
  • Table 21: Point-of-Care Molecular Diagnostics Market in India (2023-2034)
  • Table 22: Point-of-Care Molecular Diagnostics Market in Australia (2023-2034)
  • Table 23: Point-of-Care Molecular Diagnostics Market in South Korea (2023-2034)
  • Table 24: Point-of-Care Molecular Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Point-of-Care Molecular Diagnostics Market in the Rest of the World (2023-2034)
  • Table 26: Point-of-Care Molecular Diagnostics Market in the Middle East (2023-2034)
  • Table 27: Point-of-Care Molecular Diagnostics Market in Africa (2023-2034)
  • Table 28: Point-of-Care Molecular Diagnostics Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Point-of-Care Molecular Diagnostics Market Drivers
  • Figure 2: Point-of-Care Molecular Diagnostics Market Restraints
  • Figure 3: Point-of-Care Molecular Diagnostics Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Point-of-Care Molecular Diagnostics Market in Global (2023-2034)
  • Figure 9: Point-of-Care Molecular Diagnostics Market in Global by Product (2023-2034)
  • Figure 10: Point-of-Care Molecular Diagnostics Market in Global by Technology (2023-2034)
  • Figure 11: Point-of-Care Molecular Diagnostics Market in Global by Application (2023-2034)
  • Figure 12: Point-of-Care Molecular Diagnostics Market in Global by End User (2023-2034)
  • Figure 13: Point-of-Care Molecular Diagnostics Market in Global by Geography (2023-2034)
  • Figure 14: Point-of-Care Molecular Diagnostics Market in North America (2023-2034)
  • Figure 15: Point-of-Care Molecular Diagnostics Market in the United States (2023-2034)
  • Figure 16: Point-of-Care Molecular Diagnostics Market in Canada (2023-2034)
  • Figure 17: Point-of-Care Molecular Diagnostics Market in Mexico (2023-2034)
  • Figure 18: Point-of-Care Molecular Diagnostics Market in Europe (2023-2034)
  • Figure 19: Point-of-Care Molecular Diagnostics Market in Germany (2023-2034)
  • Figure 20: Point-of-Care Molecular Diagnostics Market in United Kingdom (2023-2034)
  • Figure 21: Point-of-Care Molecular Diagnostics Market in France (2023-2034)
  • Figure 22: Point-of-Care Molecular Diagnostics Market in Italy (2023-2034)
  • Figure 23: Point-of-Care Molecular Diagnostics Market in Spain (2023-2034)
  • Figure 24: Point-of-Care Molecular Diagnostics Market in the Rest of Europe (2023-2034)
  • Figure 25: Point-of-Care Molecular Diagnostics Market in Asia-Pacific (2023-2034)
  • Figure 26: Point-of-Care Molecular Diagnostics Market in China (2023-2034)
  • Figure 27: Point-of-Care Molecular Diagnostics Market in Japan (2023-2034)
  • Figure 28: Point-of-Care Molecular Diagnostics Market in India (2023-2034)
  • Figure 29: Point-of-Care Molecular Diagnostics Market in Australia (2023-2034)
  • Figure 30: Point-of-Care Molecular Diagnostics Market in South Korea (2023-2034)
  • Figure 31: Point-of-Care Molecular Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Point-of-Care Molecular Diagnostics Market in the Rest of the World (2023-2034)
  • Figure 33: Point-of-Care Molecular Diagnostics Market in the Middle East (2023-2034)
  • Figure 34: Point-of-Care Molecular Diagnostics Market in Africa (2023-2034)
  • Figure 35: Point-of-Care Molecular Diagnostics Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding and Investment Trends